company background image
2633 logo

Jacobson Pharma Informe acción SEHK:2633

Último precio

HK$0.57

Capitalización de mercado

HK$1.1b

7D

1.8%

1Y

-38.0%

Actualizada

04 May, 2024

Datos

Finanzas de la empresa

Jacobson Pharma Corporation Limited

Informe acción SEHK:2633

Capitalización de mercado: HK$1.1b

Resumen de acción 2633

Jacobson Pharma Corporation Limited, a través de sus filiales, produce, comercializa y vende medicamentos genéricos y productos sanitarios de marca en Hong Kong, China continental, Macao, Singapur e internacionalmente.

2633 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends4/6

Competidores de Jacobson Pharma Corporation Limited

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Jacobson Pharma
Historical stock prices
Current Share PriceHK$0.57
52 Week HighHK$1.08
52 Week LowHK$0.54
Beta0.43
1 Month Change-1.72%
3 Month Change-3.39%
1 Year Change-38.04%
3 Year Change-30.49%
5 Year Change-63.23%
Change since IPO-66.07%

Noticias y actualizaciones recientes

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Recent updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Rentabilidad de los accionistas

2633HK PharmaceuticalsMercado HK
7D1.8%3.4%2.2%
1Y-38.0%-13.5%-7.9%

Rentabilidad vs. Industria: 2633 obtuvo unos resultados inferiores a los del sector Hong Kong Pharmaceuticals , que el año pasado arrojó un rendimiento del -15.9%.

Rentabilidad vs. Mercado: 2633 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.1% el año pasado.

Volatilidad de los precios

Is 2633's price volatile compared to industry and market?
2633 volatility
2633 Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement7.5%
10% most volatile stocks in HK Market14.9%
10% least volatile stocks in HK Market3.7%

Precio estable de las acciones: 2633 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 2633 (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
20161,588Derek Sumwww.jacobsonpharma.com

Jacobson Pharma Corporation Limited, a través de sus filiales, produce, comercializa y vende medicamentos genéricos y productos sanitarios de marca en Hong Kong, China continental, Macao, Singapur e internacionalmente. La empresa ofrece medicamentos genéricos para diversas categorías terapéuticas, como las respiratorias, cardiovasculares, del sistema nervioso central, gastrointestinales, genitourinarias, musculoesqueléticas, endocrinas y metabólicas, dermatológicas, antialérgicas, tratamiento de cicatrices, antidiabéticas orales y antiinfecciosas, así como soluciones orales de trióxido de arsénico. También suministra medicamentos de marca; productos de salud y bienestar; y medicamentos chinos patentados, como píldoras Po Chai, Ho Chai Kung y aceite Shiling, así como productos Contractubex, Smartfish, Rowatanal, Oncotype DX y AIM Atropine.

Resumen de fundamentos de Jacobson Pharma Corporation Limited

¿Cómo se comparan los beneficios e ingresos de Jacobson Pharma con su capitalización de mercado?
Estadísticas fundamentales de 2633
Capitalización bursátilHK$1.14b
Beneficios(TTM)HK$244.99m
Ingresos (TTM)HK$1.92b

4.7x

Ratio precio-beneficio (PE)

0.6x

Ratio precio-ventas (PS)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 2633
IngresosHK$1.92b
Coste de los ingresosHK$1.12b
Beneficio brutoHK$794.44m
Otros gastosHK$549.46m
BeneficiosHK$244.99m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)0.12
Margen bruto41.41%
Margen de beneficio neto12.77%
Ratio deuda/patrimonio55.6%

¿Cómo se ha desempeñado 2633 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

8.6%

Rentabilidad actual por dividendo

38%

Ratio de pagos